GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib.
Saved in:
| Title: | GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib. |
|---|---|
| Authors: | Mathuram TL; Department of Stem Cell and Tissue Engineering, Frontier Mediville (A Unit of Frontier Lifeline and Dr. K. M. Cherian Heart Foundation), Affiliated to University of Madras, Chennai, Tamil Nadu, India., Reece LM; Sealy Center for Vaccine Development, World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA., Cherian KM; Department of Cardiothoracic Surgery, Frontier Lifeline Hospital, Chennai, Tamil Nadu, India. |
| Source: | Drug research [Drug Res (Stuttg)] 2018 Aug; Vol. 68 (8), pp. 436-443. Date of Electronic Publication: 2018 Jan 31. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Thieme Country of Publication: Germany NLM ID: 101602406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2194-9387 (Electronic) Linking ISSN: 21949379 NLM ISO Abbreviation: Drug Res (Stuttg) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2194-9387 |
|---|---|
| DOI: | 10.1055/s-0044-100186 |
